DHR Stock Forecast 2025-2026
Distance to DHR Price Targets
DHR Price Momentum
🤔 Considering Danaher (DHR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest DHR Stock Price Targets & Analyst Predictions
Based on our analysis of 34 Wall Street analysts, DHR has a bullish consensus with a median price target of $267.50 (ranging from $240.00 to $310.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $210.74, the median forecast implies a 26.9% upside. This outlook is supported by 21 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Knight at Keybanc, projecting a 47.1% upside. Conversely, the most conservative target is provided by Brandon Couillard at Wells Fargo, suggesting a 13.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DHR Analyst Ratings
DHR Price Target Range
Latest DHR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DHR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | Stifel | Daniel Arias | Buy | Upgrade | $260.00 |
| Feb 3, 2025 | Raymond James | Andrew Cooper | Market Perform | Downgrade | $0.00 |
| Jan 30, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $240.00 |
| Jan 30, 2025 | RBC Capital | Conor McNamara | Outperform | Reiterates | $277.00 |
| Jan 30, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $258.00 |
| Jan 30, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $265.00 |
| Jan 30, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $240.00 |
| Jan 29, 2025 | Jefferies | Tycho Peterson | Buy | Maintains | $260.00 |
| Jan 21, 2025 | Raymond James | Andrew Cooper | Outperform | Maintains | $275.00 |
| Jan 6, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $285.00 |
| Dec 23, 2024 | Scotiabank | Sector Perform | Initiates | $0.00 | |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Upgrade | $290.00 |
| Oct 31, 2024 | Wolfe Research | Doug Schenkel | Outperform | Upgrade | $285.00 |
| Oct 23, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $315.00 |
| Oct 23, 2024 | Raymond James | Andrew Cooper | Outperform | Maintains | $300.00 |
| Oct 23, 2024 | UBS | Dan Leonard | Buy | Maintains | $305.00 |
| Oct 23, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $315.00 |
| Oct 23, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $277.00 |
| Oct 23, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $311.00 |
| Oct 23, 2024 | Keybanc | Paul Knight | Overweight | Maintains | $310.00 |
Danaher Corporation (DHR) Competitors
The following stocks are similar to Danaher based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Danaher Corporation (DHR) Financial Data
Danaher Corporation has a market capitalization of $150.62B with a P/E ratio of 39.8x. The company generates $23.88B in trailing twelve-month revenue with a 16.3% profit margin.
Revenue growth is +2.1% quarter-over-quarter, while maintaining an operating margin of +22.5% and return on equity of +7.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Danaher Corporation (DHR) Business Model
About Danaher Corporation
Provides industrial and healthcare technology solutions.
Danaher Corporation generates revenue through the design, manufacturing, and sale of products across diagnostics, life sciences, dental, and environmental sectors. The company leverages its innovative technologies to serve a wide range of industries, ensuring high demand for its advanced solutions.
Headquartered in Washington, D.C., Danaher is known for its operational excellence through the Danaher Business System (DBS), which focuses on continuous improvement and innovation. The company's strategic acquisitions further enhance its market position and ability to deliver impactful solutions across various sectors.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
61,000
CEO
Mr. Rainer M. Blair
Country
United States
IPO Year
1987
Website
www.danaher.comDanaher Corporation (DHR) Latest News & Analysis
Beckman Coulter Diagnostics announced FDA 510(k) clearance for its new DxC 500i Clinical Analyzer, enhancing flexibility and scalability in clinical chemistry and immunoassays.
The FDA clearance of the DxC 500i Analyzer enhances Beckman Coulter's product portfolio, potentially increasing market share and revenue, positively impacting investor confidence and stock performance.
DHR's performance is affected by ongoing weakness in the Life Sciences segment and rising operating expenses.
DHR's weak Life Sciences performance and rising operating expenses signal potential profitability issues, likely affecting stock valuation and investor confidence.
Danaher Corporation (NYSE:DHR) participated in the TD Cowen 45th Annual Health Care Conference on March 5, 2025, featuring CEO Rainer Blair.
Danaher Corporation's participation in a major healthcare conference highlights its strategic focus on tools and diagnostics, potentially influencing investor confidence in its growth prospects.
DHR is implementing strategies to reward shareholders through dividends and share buybacks, signaling a commitment to returning value to investors.
DHR's commitment to dividends and share buybacks signals financial stability and a shareholder-friendly approach, potentially enhancing stock value and attracting long-term investors.
Industrial laser marking machines utilize laser technology for precise engraving, etching, or marking on materials, serving purposes like identification, branding, and tracking.
The growth of industrial laser marking technology indicates increased demand in manufacturing sectors, potentially boosting sales for companies involved in this market and enhancing their stock value.
Danaher Corporation CEO Rainer M. Blair will present at the TD Cowen Healthcare Conference on March 5, 2025, at 10:30 a.m. ET in Boston.
Danaher's CEO presentation at a major healthcare conference could signal strategic insights or developments, influencing investor sentiment and stock performance.
Frequently Asked Questions About DHR Stock
What is Danaher Corporation's (DHR) stock forecast for 2025?
Based on our analysis of 34 Wall Street analysts, Danaher Corporation (DHR) has a median price target of $267.50. The highest price target is $310.00 and the lowest is $240.00.
Is DHR stock a good investment in 2025?
According to current analyst ratings, DHR has 21 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $210.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DHR stock?
Wall Street analysts predict DHR stock could reach $267.50 in the next 12 months. This represents a 26.9% increase from the current price of $210.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Danaher Corporation's business model?
Danaher Corporation generates revenue through the design, manufacturing, and sale of products across diagnostics, life sciences, dental, and environmental sectors. The company leverages its innovative technologies to serve a wide range of industries, ensuring high demand for its advanced solutions.
What is the highest forecasted price for DHR Danaher Corporation?
The highest price target for DHR is $310.00 from Paul Knight at Keybanc, which represents a 47.1% increase from the current price of $210.74.
What is the lowest forecasted price for DHR Danaher Corporation?
The lowest price target for DHR is $240.00 from Brandon Couillard at Wells Fargo, which represents a 13.9% increase from the current price of $210.74.
What is the overall DHR consensus from analysts for Danaher Corporation?
The overall analyst consensus for DHR is bullish. Out of 34 Wall Street analysts, 21 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $267.50.
How accurate are DHR stock price projections?
Stock price projections, including those for Danaher Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
